| Literature DB >> 28955231 |
Chenguang Niu1, Fei Xiao2, Keyong Yuan1, XuChen Hu1, Wenzhen Lin1, Rui Ma1, Xiaoling Zhang2, Zhengwei Huang1.
Abstract
Periodontitis is a chronic inflammatory disease that damages the integrity of the tooth-supporting tissues, known as the periodontium, and comprising the gingiva, periodontal ligament and alveolar bone. In this study, the effects of nardosinone (Nd) on bone were tested in a model of lipopolysaccharide (LPS)-induced alveolar bone loss, and the associated mechanisms were elucidated. Nd effectively suppressed LPS-induced alveolar bone loss and reduced osteoclast (OC) numbers in vivo. Nd suppressed receptor activator of nuclear factor-κB ligand (RANKL)-mediated OC differentiation, bone resorption, and F-actin ring formation in a dose-dependent manner. Further investigation revealed that Nd suppressed osteoclastogenesis by suppressing the ERK and JNK signaling pathways, scavenging reactive oxygen species, and suppressing the activation of PLCγ2 that consequently affects the expression and/or activity of the OC-specific transcription factors, c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1). In addition, Nd significantly reduced the expression of OC-specific markers in mouse bone marrow-derived pre-OCs, including c-Fos, cathepsin K (Ctsk), VATPase d2, and Nfatc1. Collectively, these findings suggest that Nd has beneficial effects on bone, and the suppression of OC number implies that the effect is exerted directly on osteoclastogenesis.Entities:
Keywords: MAPKs; RANKL; alveolar bone resorption; nardosinone; osteoclastogenesis
Year: 2017 PMID: 28955231 PMCID: PMC5601052 DOI: 10.3389/fphar.2017.00626
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810